82W Stock Chart & Stats
€25.06
-€0.84(-3.24%)
At close: 4:00 PM EDT
€25.06
-€0.84(-3.24%)
Day’s Range― - ―
52-Week Range€11.82 - €55.00
Previous CloseN/A
Volume3.75K
Average Volume (3M)6.38K
Market Cap
€6.37B
Enterprise Value€8.74K
Total Cash (Recent Filing)€841.05M
Total Debt (Recent Filing)€1.55B
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Nov 09, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding223,080,080
10 Day Avg. Volume4,033
30 Day Avg. Volume6,379
Financial Highlights & Ratios
PEG Ratio-33.04
Price to Book (P/B)13.50
Price to Sales (P/S)3.11
P/FCF Ratio98.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€29.25Price Target Upside16.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.11
Revenue Forecast (FY)€2.54B
Bulls Say, Bears Say
Bulls Say
Strong Revenue & Subscriber GrowthSustained high revenue growth and rapid subscriber adds indicate durable demand for the DTC telehealth model. Large recurring subscriber base improves lifetime value, supports cross-sell of specialties, and creates a predictable revenue stream that underpins multi‑period scale and product expansion.
Positive Operating Cash Flow & Free Cash FlowGenerating positive operating and free cash flow despite a TTM GAAP loss shows underlying cash economics and ability to self-fund growth. This durable cash generation reduces reliance on equity dilution and supports reinvestment in marketing, fulfillment, and AI efficiency programs.
Meaningful International Scale From Eucalyptus DealAcquiring Eucalyptus materially diversifies geographic exposure and regulatory know‑how, accelerating international revenue scale. Broader footprint improves addressable market, local market expertise, and data/network effects that can lower customer acquisition costs and sustain long-term growth.
Bears Say
Rapidly Rising LeverageMaterial increase in debt materially reduces financial flexibility and raises refinancing and interest risks. High leverage amplifies downside if profitability or cash flow weaken, constrains strategic optionality, and can force capital allocation toward debt service rather than growth investments.
Gross Margin Compression From Mix ShiftA strategic shift into lower‑margin branded weight‑loss products and international sales is compressing unit economics. Unless offset by scale efficiencies or higher prices, the structural mix change can permanently lower gross margins and pressure operating profitability over the medium term.
Regulatory And Legal UncertaintyActive FTC litigation and dependence on FDA rulemaking for peptides introduce prolonged legal and timing risk. These regulatory headwinds can delay product launches, increase compliance costs, and create uncertainty around growth prospects and margins for several quarters to years.
Hims & Hers Health News
82W FAQ
What was Hims & Hers Health’s price range in the past 12 months?
Hims & Hers Health lowest stock price was €11.81 and its highest was €55.00 in the past 12 months.
What is Hims & Hers Health’s market cap?
Hims & Hers Health’s market cap is €6.37B.
When is Hims & Hers Health’s upcoming earnings report date?
Hims & Hers Health’s upcoming earnings report date is Nov 09, 2026 which is in 88 days.
How were Hims & Hers Health’s earnings last quarter?
Hims & Hers Health released its earnings results on Aug 10, 2026. The company reported -€0.321 earnings per share for the quarter, missing the consensus estimate of -€0.043 by -€0.277.
Is Hims & Hers Health overvalued?
According to Wall Street analysts Hims & Hers Health’s price is currently Undervalued.
Does Hims & Hers Health pay dividends?
Hims & Hers Health does not currently pay dividends.
What is Hims & Hers Health’s EPS estimate?
Hims & Hers Health’s EPS estimate is 0.06.
How many shares outstanding does Hims & Hers Health have?
Hims & Hers Health has 223,080,080 shares outstanding.
What happened to Hims & Hers Health’s price movement after its last earnings report?
Hims & Hers Health reported an EPS of -€0.321 in its last earnings report, missing expectations of -€0.043. Following the earnings report the stock price went down -2.466%.
Which hedge fund is a major shareholder of Hims & Hers Health?
Currently, no hedge funds are holding shares in DE:82W
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hims & Hers Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€29.25 (16.72% Upside)
€29.25 (16.72% Upside)
Blogger Sentiment
Bullish
DE:82W Sentiment 73%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €296.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 82%
Bearish news 18%
Bearish news 18%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-50.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
93.27%
Trailing 12-Months
Company Description
Hims & Hers Health
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.
82W Company Deck
82W Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive and growth-oriented outlook: strong revenue and subscriber growth, raised guidance, meaningful international scale from the Eucalyptus acquisition, and promising AI-driven engagement and efficiency gains. These positives are tempered by margin compression from mix shift toward branded weight loss and international sales, a GAAP loss driven by one-time costs, short-term negative cash flow in the quarter, and regulatory/legal uncertainties (FTC action and dependence on FDA rulemaking for peptides). Management highlighted liquidity actions and expects AI investments to pay back within 12–18 months, signaling confidence in the path to improved profitability.View all DE:82W earnings summaries82W Revenue Breakdown
96.60% Online
3.40% Wholesale
82W Stock 12 Month Forecast
Average Price Target
€29.25
▲(16.72% Upside)